Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TLR4 | O00206 | 12/20 | 0.46 |
| ▸ | LY96 | Q9Y6Y9 | 6/20 | 0.40 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.38 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.38 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4205330 | 1.00 | MAPK1 (0.47) | MAPK1TLR4LY96LGALS8LGALS3 | |
| SCHEMBL4204256 | 0.89 | MAPK1 (0.52) | MAPK1TLR4LY96LGALS8LGALS3 | |
| SCHEMBL4204252 | 0.89 | MAPK1 (0.52) | MAPK1TLR4LY96LGALS8LGALS3 | |
| SCHEMBL4205410 | 0.84 | MAPK1 (0.45) | MAPK1LGALS8LGALS3LGALS4SLC2A1 | |
| SCHEMBL4191763 | 0.80 | TLR4 (0.36) | MAPK1TLR4LY96 | |
| SCHEMBL12763047 | 0.79 | MAPK1 (0.49) | MAPK1TLR4LY96LGALS8LGALS3 | |
| SCHEMBL12560669 | 0.79 | MAPK1 (0.49) | MAPK1TLR4LY96LGALS8LGALS3 | |
| SCHEMBL12762965 | 0.79 | MAPK1 (0.49) | MAPK1TLR4LY96LGALS8LGALS3 | |
| SCHEMBL12560694 | 0.79 | MAPK1 (0.49) | MAPK1TLR4LY96LGALS8LGALS3 | |
| SCHEMBL12560771 | 0.77 | MAPK1 (0.68) | MAPK1LGALS8LGALS3LGALS4SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062214-A1 | Left-Side Glucose Lipid a Analogue | SANKYO COMPANY, LTD. (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1702926-A1 | LEVULOSE GLUCOSELIPID A ANALOGUE | Sankyo Company, Limited (JP) | 2006-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062214-A1 | Left-Side Glucose Lipid a Analogue | SLC2A3, GPR119, SLC2A2 | MAPK1 1294/4885TLR4 294/4885LY96 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.